Acrivon Therapeutics Confirms Emerging Growth Company Status

Ticker: ACRV · Form: 8-K · Filed: Jan 8, 2024 · CIK: 1781174

Acrivon Therapeutics, Inc. 8-K Filing Summary
FieldDetail
CompanyAcrivon Therapeutics, Inc. (ACRV)
Form Type8-K
Filed DateJan 8, 2024
Risk Levelmedium
Pages2
Reading Time2 min
Key Dollar Amounts$0.001
Sentimentneutral

Complexity: simple

Sentiment: neutral

Topics: regulatory-filing, emerging-growth-company

TL;DR

**ACRV confirms emerging growth status, meaning lighter regulations for now.**

AI Summary

Acrivon Therapeutics, Inc. filed an 8-K on January 8, 2024, to disclose that it is an emerging growth company, as defined by the Securities Act of 1933 and the Securities Exchange Act of 1934. This status allows the company to take advantage of certain reduced reporting requirements. This matters to investors because it indicates the company is still in a relatively early stage of development, which can imply higher growth potential but also increased risk due to less stringent regulatory oversight compared to larger, more established companies.

Why It Matters

This filing confirms Acrivon Therapeutics' status as an 'emerging growth company,' which means it benefits from reduced regulatory burdens, potentially saving costs but also offering less transparency to investors.

Risk Assessment

Risk Level: medium — The 'emerging growth company' status allows for reduced disclosure, which can mean less information for investors to assess risk, making it a medium risk.

Analyst Insight

Investors should be aware that Acrivon Therapeutics, as an emerging growth company, may provide less detailed financial and operational disclosures than larger companies, requiring more independent due diligence.

Key Numbers

  • 001-41551 — Commission File Number (identifies Acrivon Therapeutics with the SEC)
  • 82-5125532 — IRS Employer Identification No. (identifies Acrivon Therapeutics for tax purposes)
  • $0.001 — par value per share (par value of Acrivon Therapeutics' Common Stock)

Key Players & Entities

  • Acrivon Therapeutics, Inc. (company) — the registrant filing the 8-K
  • Securities Act of 1933 (other) — federal law defining emerging growth companies
  • Securities Exchange Act of 1934 (other) — federal law defining emerging growth companies
  • Nasdaq Stock Market LLC (company) — exchange where ACRV common stock is registered
  • ACRV (other) — trading symbol for Acrivon Therapeutics, Inc.

Forward-Looking Statements

  • Acrivon Therapeutics will continue to operate under reduced reporting requirements for the foreseeable future. (Acrivon Therapeutics, Inc.) — high confidence, target: 2025-01-08

FAQ

What is the primary purpose of Acrivon Therapeutics, Inc.'s 8-K filing on January 8, 2024?

The primary purpose of Acrivon Therapeutics, Inc.'s 8-K filing on January 8, 2024, is to indicate by check mark that the registrant is an 'emerging growth company' as defined in Rule 405 of the Securities Act of 1933 and Rule 12b-2 of the Securities Exchange Act of 1934.

What is Acrivon Therapeutics, Inc.'s trading symbol and on which exchange is its common stock registered?

Acrivon Therapeutics, Inc.'s trading symbol is ACRV, and its common stock, with a $0.001 par value, is registered on The Nasdaq Stock Market LLC.

What is the date of the earliest event reported in this 8-K filing?

The date of the earliest event reported in this 8-K filing is January 8, 2024.

Where are Acrivon Therapeutics, Inc.'s principal executive offices located?

Acrivon Therapeutics, Inc.'s principal executive offices are located at 480 Arsenal Way, Suite 100, Watertown, Massachusetts, 02472.

What is the Commission File Number for Acrivon Therapeutics, Inc.?

The Commission File Number for Acrivon Therapeutics, Inc. is 001-41551.

Filing Stats: 561 words · 2 min read · ~2 pages · Grade level 11.1 · Accepted 2024-01-08 07:28:34

Key Financial Figures

  • $0.001 — nge on which registered Common Stock, $0.001 par value ACRV The Nasdaq Stock Mar

Filing Documents

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure Beginning on January 8, 2023, Acrivon Therapeutics, Inc. (the "Company") will participate in the 42nd Annual J.P. Morgan Healthcare Conference. The Company has updated its corporate presentation that it intends to use in connection with its presentation on January 11, 2024 at 2:15 PM Eastern Time and in meetings with investors. The presentation includes, among other things, information on the development of the Company's product candidates and confirmation of its projected cash runway into the second half of 2025. A copy of the Company's corporate presentation is attached hereto as Exhibit 99.1 and is hereby incorporated by reference herein. The information furnished under Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1, is being furnished and shall not be deemed to be "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits: Exhibit Number Exhibit Description 99.1 Acrivon Therapeutics, Inc. Presentation 104 Cover Page Interactive Data File (formatted as Inline XBRL).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Acrivon Therapeutics, Inc. Dated: January 8, 2024 By: /s/ Peter Blume-Jensen Name: Peter Blume-Jensen, M.D., Ph.D. Title: Chief Executive Officer and President

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.